Galderma Group

Galderma Group Equity

The The Equity of Galderma Group (GALD.SW) as of Nov 6, 2026 is 6.66 B USD. In the previous year, The Equity was 7.79 B USD — a change of -14.53% (lower).

Equity

6.66 BUSD

YoY

-14.53%

Last updated:

In 2025, Galderma Group's equity was 6.66 B USD, a -14.53% increase from the 7.79 B USD equity in the previous year.

The Galderma Group Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2021
3.70 B USD
Jan 1, 2022
4.47 B USD
Jan 1, 2023
5.28 B USD
Jan 1, 2024
7.79 B USD
Jan 1, 2025
6.66 B USD
The Galderma Group Equity history
YEAREquityYoY
6.66 BUSD-14.53%
7.79 BUSD+47.60%
5.28 BUSD+18.07%
4.47 BUSD+20.74%
3.70 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Galderma Group Stock analysis

What does Galderma Group do? Galderma Group AG, headquartered in Switzerland, operates in the healthcare sector, specializing in dermatological treatments and skincare solutions. The company serves global markets with a focus on innovative products for skin health. Listed on the stock exchange in March 2024, Galderma continues to expand its presence in the international healthcare industry. Galderma Group is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Galderma Group's Equity

Galderma Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Galderma Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Galderma Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Galderma Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Galderma Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Galderma Group stock

The Equity of Galderma Group is 6.66 B USD in 2025.

The Equity of Galderma Group changed from 7.79 B USD to 6.66 B USD, representing a -14.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Galderma Group since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Galderma Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Galderma Group

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Galderma Group